Oxcia AB (Sweden), a clinical-stage company focused on oxidative DNA damage and DNA Damage Response (DDR) biology, has received Canadian patent approval for OXC-201, its preclinical small molecule candidate targeting idiopathic pulmonary fibrosis (IPF). The OXC-201 patent Canada approval extends a portfolio that already covers the US, Japan, and China, with a European Patent Office (EPO) application still pending, and protection running through March 2039. The grant reinforces Oxcia’s intellectual property position ahead of a planned first-in-human Phase I trial scheduled for early 2027.
OXC-201 is designed around Oxcia’s proprietary O2-DDR platform, which targets oxidative stress pathways implicated in fibrotic disease progression. In IPF, chronic oxidative DNA damage and dysregulated DDR signaling are understood to contribute to aberrant fibroblast activation and progressive lung tissue remodeling. The company has not disclosed the specific molecular target or binding mechanism for OXC-201 beyond its association with oxidative stress and DDR biology. Specific preclinical efficacy or pharmacological data for OXC-201 remain undisclosed in available materials.
The European Innovation Council awarded Oxcia EUR 2.5 million under the EIC-Transition program in early 2023, providing non-dilutive capital to support the preclinical-to-clinical transition for OXC-201.
The composition of matter patent, which protects the chemical compound itself rather than a specific formulation or use, represents the broadest available form of pharmaceutical intellectual property. With exclusivity extending to March 2039, the patent term covers the full anticipated clinical development window and, if the asset reaches approval, a meaningful portion of any commercial lifecycle.
Competitive landscape
The IPF treatment space is currently anchored by two approved antifibrotic agents, both of which represent the standard of care against which any new entrant will be benchmarked.